Novartis Investigative Site

Qingdao 266061

2 studies enrolling now · 7 studies all time

What they study most

Early Breast Cancer, Generalized Myasthenia Gravis, IgA Nephropathy, Metastatic Breast Cancer, Neoplasms, Gastrointestinal Tract, Primary IgA Nephropathy, Resistant Hypertension

Studies at this site

• A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis — Recruiting now
• Phase IIIb Study of Ribociclib + ET in Early Breast Cancer — Recruiting now
• A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy — Running, not enrolling
• Roll-over Study to Allow Continued Access to Ribociclib — Running, not enrolling
• An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. — Completed
• Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients — Completed
• LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib — Completed